Physician profile
Ashleigh Stroble
NPI 1568834901
$2,980.73
in general payments reported to CMS, 2019-2025
19 companies · $669 in 2025
The $669 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $439 · 2023: $898 · 2024: $718 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,285.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $721.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $383.58 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $231.34 | 2024-2025 | Airsupra |
| Optinose US, INC. | $224.69 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $151.17 | 2022-2023 | Recorlev |
| Edwards Lifesciences Corporation | $147.32 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $124.63 | 2022 | |
| Glaxosmithkline, LLC. | $124.52 | 2024 | Nucala |
| Biohaven Pharmaceuticals, INC. | $121.84 | 2021 | |
| Bioxcel Therapeutics, INC. | $106.53 | 2023 | Igalmi |
| Otsuka America Pharmaceutical, INC. | $95.63 | 2023 | Rexulti |
| Alnylam Pharmaceuticals INC. | $94.12 | 2023 | Givlaari |
| Phathom Pharmaceuticals, INC. | $93.24 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $83.64 | 2024 | Ultomiris |
| Idorsia Pharmaceuticals US INC | $76.50 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $75.60 | 2022 | |
| Stryker Corporation | $48.55 | 2022 | |
| Kaleo, INC. | $42.27 | 2021 | |
| Hikma Pharmaceuticals USA | $33.99 | 2024-2025 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Stroble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.